THOMAS MONTICELLO, PhD, DVM, DIPLOMATE OF ACVP
IQ Board of Directors Member (2015-Present)
IQ DruSafe Chair (2019)
IQ DruSafe (2012-Present)
Executive Director, Amgen
PhD, Pathology, Duke University
WHAT ARE IQ’S GREATEST ACCOMPLISHMENTS AND WHAT MAKES YOU MOST PROUD?
The large impact the IQ has made through external publications and sponsorship of scientific sessions that entails all aspects of drug development (both from the CMC and Life Sciences perspectives). I am most proud of co-chairing the DruSafe Working Group 1 - Nonclinical to Clinical Translational Database, which resulted in the establishment of the IQ data sharing agreement and the development of a robust database that is now available to other working groups.
WHAT ARE SOME HIGHLIGHTS OF YOUR ENGAGEMENT WITH THE CONSORTIUM?
CMC Leadership Group advancements in Green Chemistry
Life Science Leadership Group advancements in FIH Starting Dose, Non-clinical to Clinical Translation and Novel Bioanalytic Approaches
A welcoming and extensive network of similarly minded scientists
Development of industry lessons learned and best practices
DESCRIBE WHAT IQ IS TO YOU
Camaraderie and partnership which works as one unified team across the industry. IQ is like a very well experienced and state of the art “virtual” biopharmaceutical giant.